Pharma Antitrust & Regulation
Jury Finds Takeda Delayed Generic Constipation Drug Competition
What’s happening
A U.S. jury found that Takeda Pharmaceutical Company participated in an antitrust scheme that delayed cheaper generic versions of a constipation drug.
What’s changing / Business impact
Increased legal pressure on:
- pharmaceutical pricing strategies
- patent protection tactics
Greater scrutiny around delayed generic competition
Why this matters
Generic drugs are usually much cheaper than branded medicines.
This shows:
- governments and courts are challenging pharma tactics that delay cheaper alternatives
- drug pricing battles remain a major issue in U.S. healthcare